breast cancer

Breast Cancer's Financial Toll: Where to Go for Help

A breast cancer diagnosis can be like an earthquake in the life of the patient and her family, but the medical community is there to help guide them. What's often hard to find is a monetary lifeline for those in danger of getting washed away by the financial tidal wave that can follow.

Breast Cancer's Financial Toll: Your Money or Your Life

Breast cancer is the second most common cancer among American women: 12% will develop it at some point in their lives, and at that point, the health battle begins. But those women often must fight one a second front as well, dealing with the multiple threats cancer poses to their financial well-being.

Perfume to Benefit Breast Cancer May Also Cause Cancer

The Susan G. Komen Foundation's partnerships bring in millions each year for breast cancer research. But one of its partners has brought it an ironic problem: The perfume Promise Me, marketed to benefit the charity, contains a hormone disruptor that studies point to as a contributing cause of breast cancer.

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

Wyeth Loses Appeal Over Hormone Replacement Drugs

Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer.

Setback for Roche and Immunogen Breast Cancer Drug

The FDA denied accelerated approval of Roche's trastuzumab-DM1 (T-DM1) license application. T-DM1 is a potential breast cancer treatment. Roche will continue with its trials and plans a global regulatory submission in mid-2012.

Will FDA Withdraw Avastin Approval for Breast Cancer?

Roche's blockbuster cancer drug, Avastin, could lose its U.S. Food and Drug Administration approval for use against breast cancer after an FDA panel recommended the withdrawal. Studies failed to show the drug extends breast-cancer patients' lives, panelists say.

A Judge Rules: 'You Can't Patent Nature'

District Judge Robert Sweet has invalidated patents Myriad Genetics holds on naturally occurring snippets of human DNA. At issue are genetic tests for breast and ovarian cancer, but the ruling could upend the whole biotech industry -- if it survives appeals.

Breast Cancer Screening: Why Can't Experts Agree?

A new study finds that screening women for breast cancer failed to significantly reduce deaths in Danish women. This contrasts with earlier results, including a 25% drop in breast cancer mortality in Copenhagen after mammography screening was introduced.

Breast Cancer Fears Grow Around Household Cleaners

Doctors and environmental scientists are growing more concerned that chemicals found in many household cleaning supplies, such as floor cleaners and glass cleaners, are behind the ongoing increase in breast cancer cases in the U.S. Anecdotal evidence from some of the latest epidemiological data suggests that younger women (and a growing number of men) are contracting the cancer.